Beam Therapeutics said updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency (AATD) showed restored functional protein production across multiple dose groups. The company reported that treated patients surpassed an intended protective threshold and also saw average reductions of more than 80% in circulating misfolded alpha-1 antitrypsin levels.